Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy?

Septerna, Inc. (NASDAQ:SEPN) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $28.99 and last traded at $27.09, with a volume of 365987 shares changing hands. The stock had previously closed at $24.28.

Analyst Ratings Changes

SEPN has been the topic of a number of research analyst reports. Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target for the company. Finally, TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock.

Septerna Stock Down 4.4 %

The business’s 50-day moving average price is $23.72.

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of Septerna stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.